EVAX (Evaxion AS) ROE %: 0.00% (As of Mar. 2026)


EVAX Evaxion AS EVAX
22 GF Score
Price $3.23
! 2 Warning Signs
View Full Analysis

What is Evaxion AS ROE %?

Evaxion AS EVAX -1.59% 22 ROE % is 0.00% as of Mar. 2026. GuruFocus rates EVAX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,255 Biotechnology companies, Evaxion AS ranks worse than 79681.2% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Evaxion AS's annualized net income for the quarter that ended in Mar. 2026 was $-14.52 Mil. Evaxion AS's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $-58.34 Mil. Therefore, Evaxion AS's annualized ROE % for the quarter that ended in Mar. 2026 was N/A%.

The historical rank and industry rank for Evaxion AS's ROE % or its related term are showing as below:

EVAX's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -38.18
* Ranked among companies with meaningful ROE % only.

Evaxion AS  (NAS:EVAX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-14.516/-58.3425
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-14.516 / 0)*(0 / 26.025)*(26.025 / -58.3425)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*N/A
=ROA %*Equity Multiplier
=N/A %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-14.516/-58.3425
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-14.516 / -15.38) * (-15.38 / -15.276) * (-15.276 / 0) * (0 / 26.025) * (26.025 / -58.3425)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9438 * 1.0068 * N/A % * 0 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Evaxion AS ROE % Related Terms


Evaxion AS ROE % Historical Data

* Premium members only.

The historical data trend for Evaxion AS's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evaxion AS ROE % Chart

Evaxion AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
Get a 7-Day Free Trial Premium Member Only -124.29 -113.74 -1,238.11 0.00 -100.18

Evaxion AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -145.44 -233.25 Negative Equity 0.00 0.00

EVAX vs DARE, LITS, TVGN: ROE % Comparison

For the Biotechnology subindustry, Evaxion AS's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evaxion AS ROE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evaxion AS's ROE % distribution charts can be found below:

* The bar in red indicates where Evaxion AS's ROE % falls into.


EVAX
22GF Score
Evaxion AS EVAX
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evaxion AS ROE % Calculation

Evaxion AS's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=-7.707/( (-1.652+17.039)/ 2 )
=-7.707/7.6935
=-100.18 %

Evaxion AS's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=-14.516/( (17.039+-133.724)/ 2 )
=-14.516/-58.3425
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
Evaxion AS (EVAX) has a ROE % of 0.00% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Evaxion AS and its competitors. According to the industry distribution chart, Evaxion AS ranks #999999 out of 1255 companies in the Biotechnology industry.
Is Evaxion AS's ROE % too high?
Evaxion AS's current ROE % is 0.00%. Based on the distribution chart, Evaxion AS ranks #999999 out of 1255 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Evaxion AS has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Evaxion AS's ROE % compare to DARE and LITS?
According to the Biotechnology industry distribution chart, Evaxion AS ranks #999999 out of 1255 companies for ROE %. This places Evaxion AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Evaxion AS and its competitors. Evaxion AS's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evaxion AS stock overvalued right now?
Evaxion AS (EVAX) has a current ROE % of 0.00%. The current ROE % is 0.00%. Evaxion AS's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Evaxion AS (EVAX), the current ROE % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evaxion AS Business Description

Address Dr. Neergaards Vej 5f, Horsholm, DNK, 2970
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
22GF Score

Get the complete analysis for EVAX

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.23
Price